Compare DexCom, Inc. (DXCM) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JPMorgan Chase & Co — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while JPMorgan Chase & Co trades at $345.56 (market cap $922.16B). The key difference: JPMorgan Chase & Co is far larger — about 32.9× DexCom, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.73% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | JPM | |
|---|---|---|
Market Cap | $28.06B | $922.16B |
Sector | Health | Financials |
52-Week High | $89.53 | $346.91 |
52-Week Low | $54.84 | $282.84 |
Enterprise Value | $27.03B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
JPMorgan Chase (JPM) trades at $342.89, up 2.5% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $181.85B revenue and $57.05B net income for 2025, though recent cash flow trends show operational challenges. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. Technical indicators suggest continued upward momentum with key resistance at $346.
JPM offers solid value with a P/E of 14.86 and strong institutional support, but faces risks from negative operating cash flows and geopolitical uncertainty. The consensus price target of $372 suggests 8.5% upside potential, supported by the company's leading ROE in the banking sector and stable dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
